{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:17:43Z","timestamp":1789107463126,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.07.010","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T12:47:51Z","timestamp":1691326071000},"page":"829-837.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed\/Refractory Multiple Myeloma After Lenalidomide Exposure"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-2393","authenticated-orcid":false,"given":"Faith E.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-3888","authenticated-orcid":false,"given":"Pauline","family":"Le Nouveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.07.010_bib0001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.07.010_bib0002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","article-title":"Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity","volume":"51","author":"Cornell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2023.07.010_bib0003","series-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader","year":"2021"},{"key":"10.1016\/j.clml.2023.07.010_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.07.010_bib0005","unstructured":"REVLIMID\u24c7 (lenalidomide) [prescribing information]. 2023. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.07.010_bib0007","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7) for Multiple Myeloma Version 3.2023. \u00a9National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed: February 8, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.clml.2023.07.010_bib0008","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.07.010_bib0009","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.07.010_bib0010","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.07.010_bib0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.07.010_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.07.010_bib0013","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.07.010_bib0014","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.07.010_bib0015","unstructured":"Imnovid\u24c7 (pomalidomide) summary of product characteristics. London, UK, European Medicines Agency, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imnovid-epar-product-information_en.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0016","unstructured":"POMALYST\u24c7 (pomalidomide). Celgene, a Bristol-Myers Squibb company. Pomalidomide prescribing information (https:\/\/packageinserts.bms.com\/pi\/pi_pomalyst.pdf). 2023. Available at: http:\/\/www.celgene.com\/content\/uploads\/pomalyst-pi.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0017","unstructured":"Janssen. DARZALEX\u24c7 (daratumumab) prescribing information. 2023. Available at: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0018","unstructured":"Bristol Myers Squibb. Empliciti\u24c7 (elotuzumab) prescribing information. 2022. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0019","unstructured":"European Medicines Agency: Empliciti\u24c7 (elotuzumab) summary of product characteristics. London, UK, European Medicines Agency, 2022 Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/empliciti-epar-product-information_en.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0020","unstructured":"European Medicines Agency: Sarclisa\u24c7 (isatuximab) summary of product characteristics. London, UK, European Medicines Agency, 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0021","unstructured":"Sanofi. SARCLISA\u24c7 (isatuximab-irfc) prescribing information. 2022. Available at: https:\/\/products.sanofi.us\/Sarclisa\/Sarclisa.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0022","unstructured":"European Medicines Agency: Darzalex\u24c7 (daratumumab) summary of product characteristics. London, UK, European Medicines Agency, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf. Accessed February 8, 2023."},{"key":"10.1016\/j.clml.2023.07.010_bib0023","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.07.010_bib0024","series-title":"Systematic reviews: CRD's guidance for undertaking reviews in health care","year":"2009"},{"key":"10.1016\/j.clml.2023.07.010_bib0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2023.07.010_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2023.07.010_bib0027","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/sim.6111","article-title":"Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects","volume":"33","author":"Combescure","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2023.07.010_bib0028","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase III trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.07.010_bib0029","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.26147","article-title":"Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed\/refractory multiple myeloma: final results from the MCRN-003\/MYX.1 single arm phase II trial","volume":"96","author":"Venner","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.07.010_bib0030","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.07.010_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase III study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.07.010_bib0032","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase III trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.07.010_bib0033","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase III trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.07.010_bib0034","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase III study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.07.010_bib0036","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.010_bib0037","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134189","article-title":"Pomalidomide, dexamethasone, and daratumumab after lenalidomide treatment in relapsed refractory multiple myeloma: updated results from an open-label, multicenter, phase II trial","volume":"136","author":"Siegel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.010_bib0038","first-page":"271","article-title":"Final results of the phase (ph) I\/II study of carfilzomib, pomalidomide, and dexamethasone (KPD) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): a multi-center MMRC study","volume":"102","author":"Jakubowiak","year":"2017","journal-title":"Haematologia"},{"key":"10.1016\/j.clml.2023.07.010_bib0039","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","article-title":"Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study","volume":"32","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.07.010_bib0040","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.010_bib0041","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.07.010_bib0042","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ajh.26361","article-title":"A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)","volume":"96","author":"Voorhees","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.07.010_bib0043","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2018-99-114029","article-title":"Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide. The EMN011 trial","volume":"132","author":"Sonneveld","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:09Z","timestamp":1761871449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002288"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed\/Refractory Multiple Myeloma After Lenalidomide Exposure","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}